We differentiated iMGs (Fig. 1c, Supplementary Figs. 1f, and 2a–c) from healthy donors, FRDA patients, familial heterozygous carriers (henceforth referred as carriers) and FXN CRISPR/Cas9 gene edited lines (henceforth referred to as edited) to explore the therapeutic potential of GAA trinucleotide repeat expansion correction specifically in iMGs. Here, FXN is linked to Friedreich ataxia.